The Changing Face of Advanced Prostate Cancer (2024)

The Changing Face of Advanced Prostate Cancer 2023 Webcast (2024) CME Available: https://auau.auanet.org/node/41136 At the conclusion of this activity, participants will be able to: 1. Identify and treat a patient with newly diagnosed M1 prostate cancer with androgen deprivation therapy plus be able to offer novel ADT. Furthermore, recognize high-volume new M1 prostate cancer so as to be able to refer to a genitourinary medical oncologist for chemotherapy if necessary. 2. Diagnose M0 CRPC, and be able to educate patients about using novel oral androgen receptor inhibitors added to traditional androgen deprivation therapy as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, understand the differences between these novel oral agents and educate patients about side effects and toxicities. Finally, understand the role or lack of role of prostate-specific membrane antigen PET in working up this disease state. 3. Apply the latest phase III randomized controlled trial results for new therapies in M1 CRPC, and be able to educate their patients on treatment options and work on a multidisciplinary team caring for this disease state of far advanced prostate cancer. 4. Identify that advanced prostate cancer is a complex group of disease states with a rapidly changing therapeutic landscape, and for providers and teams to embrace the multidisciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents and novel androgen receptor-targeted agents emerging in 2024. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.